MapLight Reports Q3 2026 Financials and Outlines Plans for Confirmatory Phase 3 Trial
MapLight Therapeutics ended the quarter with $463.4 million in cash and announced initiation of ZEPHYR-2, a Phase 3 schizophrenia trial topline results of which are expected in late 2027, alongside ongoing enrollment for ADP studies.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed